首页> 美国卫生研究院文献>Thoracic Cancer >Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody

【2h】

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody

机译：在先前用抗PD-1抗体治疗的非小细胞肺癌患者中用抗PD-1抗体重新治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

This study evaluated the efficacy and safety of retreatment with anti‐programmed death 1 (anti‐PD‐1) antibodies in patients with advanced non‐small cell lung cancer (NSCLC) after prior treatment with anti‐programmed death‐ligand 1 (anti‐PD‐L1) antibodies.

机译：这项研究评估了抗程控死亡1（抗PD-1）抗体在先前接受抗程控死亡配体1（抗-PD）治疗的晚期非小细胞肺癌（NSCLC）患者中的疗效和安全性。 PD‐L1）抗体。

著录项

期刊名称 Thoracic Cancer
作者
Kohei Fujita; Yuki Yamamoto; Osamu Kanai; Misato Okamura; Masayuki Hashimoto; Koichi Nakatani; Satoru Sawai; Tadashi Mio;
展开▼
作者单位

展开▼
年(卷),期 2020(11),1
年度 2020
页码 -1
总页数 4
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Anti‐PD‐1; anti‐PD‐L1; immune checkpoint inhibitors; lung cancer; retreatment;

机译：抗PD-1;抗PD-1L;免疫检查点抑制剂;肺癌;再治疗;

相似文献

外文文献
中文文献
专利

1. Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody [J] . Kohei Fujita, Yuki Yamamoto, Osamu Kanai, Thoracic cancer. . 2020,第1期

机译：用抗PD-L1抗体治疗的非小细胞肺癌患者中的抗PD-1抗体的再处理
2. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies [J] . Fujita Kohei, Uchida Naohiro, Yamamoto Yuki, Anticancer Research: International Journal of Cancer Research and Treatment . 2019,第7期

机译：用先前用抗PD-1抗体处理的先进的非小细胞肺癌中的抗PD-L1抗体的再处理
3. Switching administration of anti‐PD ‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review [J] . Shingo Kitagawa, Taiki Hakozaki, Rui Kitadai, Thoracic cancer. . 2020,第7期

机译：切换抗PD -1和抗PD-L1抗体作为免疫检查点抑制剂在具有先进的非小细胞肺癌中的个体中重新检查：案例系列和文献综述
4. Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model [C] . Thinzar M. Lwin, Kentaro Miyake, Takashi Murakami, Molecular-Guided Surgery: Molecules, Devices, and Applications IV . 2018

机译：荧光人源化抗CEA抗体在源自患者的原位异种移植（PDOX）小鼠模型中特异性标记转移性胰腺癌
5. Human anti-histone 3.3 antibodies as potential biotherapeutics for Chronic Obstructive Pulmonary Disease (COPD). [D] . Pang, Yu. 2016

机译：人类抗组蛋白3.3抗体可作为慢性阻塞性肺疾病（COPD）的潜在生物疗法。
6. Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review [O] . Shingo Kitagawa, Taiki Hakozaki, Rui Kitadai, 2020

机译：晚期非小细胞肺癌患者中抗PD-1和抗PD-1 L1抗体的切换给药作为免疫检查点抑制剂的挑战：病例系列和文献综述
7. Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody [O] . Kohei Fujita, Yuki Yamamoto, Osamu Kanai, 2019

机译：用抗PD-L1抗体治疗的非小细胞肺癌患者中的抗PD-1抗体的再处理

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody

摘要

著录项

相似文献

相关主题

期刊订阅